Outlook Therapeutics (OTLK) EPS (Weighted Average and Diluted) (2016 - 2026)
Outlook Therapeutics (OTLK) reported EPS (Weighted Average and Diluted) of -$0.05 for Q1 2026, up 96.67% year-over-year from -$0.03 in Q1 2025, and up 86.84% quarter-over-quarter from -$0.38 in Q4 2025.
Outlook Therapeutics (OTLK) EPS (Weighted Average and Diluted) (2016 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has 10 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.05 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.05, up 96.67% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.17 (down 28.57% YoY), and the FY2025 annual result was -$1.79, up 55.91% from the prior year.
- EPS (Weighted Average and Diluted) climbed to -$0.05 in Q1 2026 per OTLK's latest filing, from -$0.38 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $0.76 in Q3 2024 and troughed at -$8.01 in Q1 2024.
- A 5-year average of -$0.85 and a median of -$0.38 in 2025 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2023 and 2024: EPS (Weighted Average and Diluted) sank 1912.5% in 2023, then surged 183.72% in 2024.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.08 in 2022, then plunged by 975.0% to -$0.86 in 2023, then surged by 183.72% to $0.72 in 2024, then plunged by 152.78% to -$0.38 in 2025, then jumped by 86.84% to -$0.05 in 2026.
- Business Quant data shows OTLK's EPS (Weighted Average and Diluted) at -$0.05 in Q1 2026, -$0.38 in Q4 2025, and -$0.19 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 0.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -0.61 |
| 10 | Outlook Therapeutics | 51.56 Mn | 43.81 Mn | -21,888.00 | -0.05 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.05 |
| Dec 31, 2025 | -0.38 |
| Sep 30, 2025 | -0.19 |
| Jun 30, 2025 | -0.55 |
| Mar 31, 2025 | -1.50 |
| Dec 31, 2024 | 0.72 |
| Sep 30, 2024 | 0.76 |
| Jun 30, 2024 | -0.89 |
| Mar 31, 2024 | -8.01 |
| Dec 31, 2023 | -0.86 |
| Sep 30, 2023 | -0.99 |
| Jun 30, 2023 | -1.61 |
| Mar 31, 2023 | -0.52 |
| Dec 31, 2022 | -0.08 |
| Sep 30, 2022 | -0.06 |
| Jun 30, 2022 | -0.08 |
| Mar 31, 2022 | -0.09 |
| Dec 31, 2021 | -0.08 |
| Sep 30, 2021 | -0.08 |
| Jun 30, 2021 | -0.07 |